Literature DB >> 28356595

Anticancer drugs: All roads lead to EZH2 inhibition.

M Teresa Villanueva.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28356595     DOI： 10.1038/nrd.2017.55

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  2 in total

1.  EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.

Authors:  Faizaan Mohammad; Simon Weissmann; Benjamin Leblanc; Deo P Pandey; Jonas W Højfeldt; Itys Comet; Chunqin Zheng; Jens Vilstrup Johansen; Nicolas Rapin; Bo T Porse; Andrey Tvardovskiy; Ole N Jensen; Nagore G Olaciregui; Cinzia Lavarino; Mariona Suñol; Carmen de Torres; Jaume Mora; Angel M Carcaboso; Kristian Helin
Journal:  Nat Med       Date:  2017-02-27       Impact factor: 53.440

2.  Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.

Authors:  Lian Dee Ler; Sujoy Ghosh; Xiaoran Chai; Aye Aye Thike; Hong Lee Heng; Ee Yan Siew; Sucharita Dey; Liang Kai Koh; Jing Quan Lim; Weng Khong Lim; Swe Swe Myint; Jia Liang Loh; Pauline Ong; Xin Xiu Sam; Dachuan Huang; Tony Lim; Puay Hoon Tan; Sanjanaa Nagarajan; Christopher Wai Sam Cheng; Henry Ho; Lay Guat Ng; John Yuen; Po-Hung Lin; Cheng-Keng Chuang; Ying-Hsu Chang; Wen-Hui Weng; Steven G Rozen; Patrick Tan; Caretha L Creasy; See-Tong Pang; Michael T McCabe; Song Ling Poon; Bin Tean Teh
Journal:  Sci Transl Med       Date:  2017-02-22       Impact factor: 17.956
  2 in total
  6 in total

1.  BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes.

Authors:  Michael C Zaiken; Ryan Flynn; Katelyn G Paz; Stephanie Y Rhee; Sujeong Jin; Fathima A Mohamed; Asim Saha; Govindarajan Thangavelu; Paul M C Park; Matthew L Hemming; Peter T Sage; Arlene H Sharpe; Michel DuPage; Jeffrey A Bluestone; Angela Panoskaltsis-Mortari; Corey S Cutler; John Koreth; Joseph H Antin; Robert J Soiffer; Jerome Ritz; Leo Luznik; Ivan Maillard; Geoffrey R Hill; Kelli P A MacDonald; David H Munn; Jonathan S Serody; William J Murphy; Leslie S Kean; Yi Zhang; James E Bradner; Jun Qi; Bruce R Blazar
Journal:  Blood       Date:  2022-05-12       Impact factor: 25.476

2.  Targeting EZH2-mediated methylation of histone 3 inhibits proliferation of pediatric acute monocytic leukemia cells in vitro.

Authors:  Abdulhameed Al-Ghabkari; Aru Narendran
Journal:  Cancer Biol Ther       Date:  2021-05-12       Impact factor: 4.742

Review 3.  Epigenetic regulation of HIV-1 latency: focus on polycomb group (PcG) proteins.

Authors:  Sheraz Khan; Mazhar Iqbal; Muhammad Tariq; Shahid M Baig; Wasim Abbas
Journal:  Clin Epigenetics       Date:  2018-02-05       Impact factor: 6.551

4.  JARID2 and the PRC2 complex regulate skeletal muscle differentiation through regulation of canonical Wnt signaling.

Authors:  Abhinav Adhikari; Judith Davie
Journal:  Epigenetics Chromatin       Date:  2018-08-17       Impact factor: 4.954

5.  Pharmacological inhibition of EZH2 by GSK126 decreases atherosclerosis by modulating foam cell formation and monocyte adhesion in apolipoprotein E-deficient mice.

Authors:  Xianjing Wei; Ying Zhang; Lianna Xie; Kaijun Wang; Xiaoqing Wang
Journal:  Exp Ther Med       Date:  2021-06-06       Impact factor: 2.447

6.  Identifying genes as potential prognostic indicators in patients with serous ovarian cancer resistant to carboplatin using integrated bioinformatics analysis.

Authors:  Shi-Jie Zhan; Bin Liu; Hua Linghu
Journal:  Oncol Rep       Date:  2018-04-19       Impact factor: 3.906
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.